The ability to manage obstructive hypertrophic cardiomyopathy (oHCM) with targeted medical therapy to provide improved symptom management and decrease the need for interventional management with alcohol septal ablation (ASA) or cardiac myomectomy has only recently become available to cardiologists caring for patients with this challenging disease. The development of cardiac myosin inhibitors (CMIs) represents a paradigm shift in the management of oHCM, enabling a mechanism-based, non-invasive treatment option. By reducing LVOT obstruction and improving functional capacity, these drugs are transforming care, particularly for patients who are inadequately controlled with conventional therapies or are poor or unwilling candidates for invasive procedures. While CMIs are now recommended in the latest US and European oHCM treatment guidelines and are utilized with rapidly increasing frequency in HCM Centers of Excellence, expert-led education is needed to inform and empower community-based clinicians to use these drugs in appropriately selected patients and to arrange suitable expert consultation and follow-up as part of an individualized treatment plan.
As CMI treatment becomes more and more widely available and practical experience with it grows, it is an opportune time to educate clinicians who manage patients with HCM about it, as well to provide updates on diagnostic and risk stratification approaches. Such education is an important step towards delivering optimal CMI care to patients in the community, regardless of the level of involvement of a CoE in that management—whether the patient is co-managed with the CoE or managed primarily in the community. Even in those situations where a CoE assumes full responsibility for patient management, community providers should be better educated on diagnostic strategies, pathophysiology that affords the opportunity for CMIs to improve outcomes, and proper monitoring of disease in between CoE visits.
Drs Desai, Owens, and Martinez lead the learner through a review of the pathophysiology, epidemiology, and diagnostic evaluation of HCM, and then review clinical trial and observational data on the use of CMIs as targeted medical therapy. This program provides an essential update on oHCM management that aligns with the 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR HCM Guidelines.
Community cardiologists and other healthcare professionals involved in the care of patients with oHCM
An improved understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM
Improved confidence and competence in diagnostic skill for recognizing HCM, and improved acumen for “triaging” those patients who need CoE management earlier than others
A clear understanding of the differences between symptom management and pathophysiology-targeted treatment for patients with HCM
Practice-pertinent awareness of the most recent clinical data on the efficacy and safety of CMIs in the management of HCM, including differences in study design and clinical applicability of endpoints
Familiarity with the most current AHA/ACC/AMSSM/HRS/PACES/SCMR guidelines addressing the management of HCM
| Faculty | Relationship Identified With: |
| Milind Desai, MD | Consultant/Advisor: Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Tenaya Therapeutics; Viz.ai, Inc. Grant/Research Support: Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Tenaya Therapeutics; Viz.ai, Inc. |
| Matthew Martinez, MD | Consultant/Advisor: Bristol Myers Squibb; Cytokinetics; Viz.ai, Inc. |
| Anjali Owens, MD | Consultant/Advisor: Alexion; Bayer; BioMarin; Bristol Myers Squibb; CorVista Health; Cytokinetics; Edgewise Therapeutics; Imbria; Lexeo Therapeutics, Inc.; Pfizer Inc.; Stealth BioTherapeutics Inc.; Tenaya Therapeutics Grant/Research Support: Bristol Myers Squibb |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.1 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-25-006-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Bristol Myers Squibb.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
